东宝生物(300239) - 2018 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2018 was CNY 452.75 million, an increase of 27.09% compared to CNY 356.24 million in 2017[22]. - The net profit attributable to shareholders for 2018 was CNY 33.98 million, representing a growth of 51.57% from CNY 22.42 million in 2017[22]. - The net cash flow from operating activities reached CNY 60.00 million, a significant increase of 2,024.98% compared to a negative cash flow of CNY 3.12 million in 2017[22]. - The total assets at the end of 2018 amounted to CNY 1.20 billion, reflecting a growth of 23.39% from CNY 971.54 million at the end of 2017[22]. - The company reported a basic earnings per share of CNY 0.0737, up 51.65% from CNY 0.0486 in the previous year[22]. - Operating profit reached 39.20 million yuan, up 48.18% compared to the previous year[36]. - The company achieved total operating revenue of ¥452,748,251.38 in 2018, representing a year-on-year increase of 27.09% compared to ¥356,244,410.51 in 2017[74]. - The company reported a gross profit margin of 21.54% for its biological and biochemical products, with a slight increase from the previous year[76]. Production Capacity Expansion - The company raised 232 million RMB through a private placement to expand gelatin and collagen production capacity, aiming for an annual production capacity of 13,500 tons of gelatin and 3,000 tons of collagen[6]. - The company is currently completing the expansion of its gelatin production from 3,500 tons to 7,000 tons, with equipment debugging in progress, while the collagen project has completed most of its construction[6]. - The company plans to expand gelatin production capacity from 10,000 tons to 13,500 tons per year and collagen capacity to 3,000 tons per year[42]. - The company has ongoing construction projects, including a new collagen production facility, which is expected to enhance future production capacity[96]. - The company has officially launched a new production line for 3,500 tons of gelatin, further solidifying its leading position in the gelatin industry[115]. Market Strategy and Development - The company plans to enhance its market presence by targeting the health market, particularly focusing on the elderly demographic, leveraging the health benefits of collagen[8]. - The company aims to develop its retail collagen brand "Yuan Su Bone Peptide" and has already penetrated the elderly and female markets with various products[9]. - The company is actively developing new markets for gelatin and collagen, focusing on high-end peptide powder markets to enhance profitability[56]. - The company is focused on establishing a world-class modern collagen biotechnology enterprise, enhancing upstream and downstream industry collaboration, and expanding raw material bases[66]. - The company aims to improve user service management and enhance user loyalty through comprehensive service capabilities and participation in industry exhibitions[69]. Research and Development - The company emphasizes R&D in new technologies and processes, maintaining a leading position in the industry[44]. - The company currently holds 18 authorized patents, including 10 Chinese invention patents and 1 utility model patent, which supports its long-term development in new technologies and products[46]. - The company has made significant advancements in the pharmaceutical health sector, particularly with a patent for a collagen peptide preparation method that inhibits cancer cell proliferation, marking a breakthrough in technology innovation[46]. - The company has published numerous research papers related to gelatin and collagen peptides, indicating its active engagement in scientific research and innovation[47]. - Research and development expenses increased by 30.46% to ¥7,794,456.53, reflecting the company's commitment to enhancing R&D efforts[85]. Financial Management and Shareholder Returns - The company has proposed a profit distribution plan, offering a cash dividend of 0.30 RMB per 10 shares to all shareholders[11]. - In 2018, the company distributed cash dividends of 0.3 RMB per 10 shares, totaling 13,826,223.24 RMB, based on a total share capital of 460,874,108 shares[135]. - The proposed cash dividend for 2018 is 0.3 RMB per 10 shares, amounting to 15,719,823.24 RMB, with a total share capital of 523,994,108 shares[139]. - The company aims to enhance shareholder returns and reduce the risk of dilution for existing shareholders[146]. - The company has committed to strictly adhere to its dividend policy to ensure shareholder returns[145]. Corporate Governance and Compliance - The company appointed Dahua Certified Public Accountants (Special General Partnership) for audit services, with a fee of 330,000 RMB, and has maintained this auditor for 7 years[153]. - The company did not engage in any related party transactions during the reporting period[160]. - The company has committed to not infringe on company interests and to ensure proper management of assets during the reporting period[142]. - The company has established a comprehensive environmental protection management system, ensuring compliance with national wastewater discharge standards without exceeding limits[179]. - The company has received honors for its contributions to social welfare, including participation in disaster relief efforts[175]. Environmental Responsibility - The company has established a comprehensive environmental risk emergency response plan to efficiently handle pollution incidents, ensuring safety and prevention as primary principles[180]. - The emergency response organization is led by the general manager and includes various specialized teams for effective incident management[180]. - The company conducts annual emergency drills related to environmental incidents to enhance the preparedness of all employees[180]. - The environmental self-monitoring program has been effectively implemented, ensuring compliance with environmental regulations[181]. - The main pollutants from the company are COD and ammonia nitrogen, with actual discharge concentrations and amounts within the approved standards[179].